Phase 3 Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are 80 years of age or older, OR people aged 65 to 79 who have been assessed as being in a weaker state of health and are not considered suitable for a standard full-dose chemotherapy treatment called R-CHOP
- People who have been diagnosed with a specific type of blood cancer called large B-cell lymphoma (LBCL) that has not been treated before, confirmed through laboratory testing of tissue samples (certain subtypes are excluded — confirm with trial site)
- People whose cancer shows up on a specific type of scan (FDG-PET) and has measurable disease according to standard medical staging guidelines
- People whose cancer is at a certain stage — from Stage I with a large tumour (7.5 cm or bigger) through to Stage IV
- People with a general health and activity level rated between 0 and 2 on a standard medical scale (meaning able to carry out at least some daily activities)
- People with bone marrow, liver, kidney, and heart function that meets the trial's minimum health requirements
Who may not be able to join:
- People with other health conditions that a doctor judges would make trial participation unsafe or difficult to complete
- People diagnosed with certain other lymphoma-related conditions, including post-transplant lymphoma, a specific type called plasmablastic lymphoma, Richter's transformation, or certain combined or previously slow-growing lymphomas
- People who have had the lymphoma spread to the brain or spine, or who have a significant existing brain or nervous system condition
- People with a known history of a rare immune system condition called hemophagocytic lymphohistiocytosis or macrophage activation syndrome (HLH/MAS)
- People with an active or uncontrolled infection
- People with significant heart abnormalities
- People who have previously received treatment for lymphoma, except for steroid medications taken to manage symptoms
- People who currently need ongoing immune-suppressing medication for an active autoimmune or inflammatory condition (some exceptions may apply — confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Michael Dickinson,, MBBS BS DMSc, Peter MacCallum Cancer Center
Phone: 1-877-240-9479
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
5 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
SRI - Safety evaluation of R-mini-CHOP × 2 followed by AZD0486: Number of participants with treatment-related adverse events.; SRI - Tolerability evaluation of R-mini-CHOP × 2 followed by AZD0486: Number of participants with treatment-related adverse events.; SRI - Determination of the recommended Phase III dose (RP3D); Phase 3 - To demonstrate the superiority of R-mini-CHOP x2 followed by AZD0486 compared to R-mini-CHOP x6 regimen.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.